A glucuronidation pathway of capecitabine occurs in rats but not in mice and humans.
Glucuronidation of 5'-DFCR, a metabolite of capecitabine, was confirmed in experimental models from rats whereas 5'-DFCR glucuronide was detected neither in bile or liver from mice nor in liver microsomes from human. Metabolic interactions at the level of the glucuronidation pathway between CAP and other drugs are unlikely in patients.
Desmoulin
F
F
Groupe de RMN Biomédicale, LSPCMIB UMR - CNRS 5068, Bât. 2R1, Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse Cedex 9, France. desmoulin@chimie.ups-tlse.fr
Claparols
C
C
Bon
D
D
Larrieu
G
G
Martino
R
R
Malet-Martino
M
M
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000378:metabolism*; D001646:Bile / Q000378:metabolism; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000378:metabolism; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000378:metabolism; D020719:Glucuronides / Q000378:metabolism*; D006801:Humans; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008862:Microsomes, Liver / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013045:Species Specificity
D000964:Antimetabolites, Antineoplastic; D020719:Glucuronides; D003841:Deoxycytidine; D000069287:Capecitabine; C418208:5'-deoxy-5-fluorocytidine; D005472:Fluorouracil